Oral Complications of Head and Neck Cancer Therapy

[1] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018] Europ J Cancer. 2018; 103:356–387 FerlayJ ColombetM SoerjomataramI Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018] Europ J Cancer 2018 103 356 387 10.1016/j.ejca.2018.07.00530100160 Search in Google Scholar

[2] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7–30 SiegelRL MillerKD JemalA Cancer Statistics, 2017 CA Cancer J Clin 2017 67 1 7 30 10.3322/caac.2138728055103 Search in Google Scholar

[3] Garavello W, Bertuccio P, Levi F, et al. The oral cancer epidemic in central and eastern Europe. Int J Cancer. 2010; 127(1):160–171 GaravelloW BertuccioP LeviF The oral cancer epidemic in central and eastern Europe Int J Cancer 2010 127 1 160 171 10.1002/ijc.2501919882710 Search in Google Scholar

[4] Taher AN. Head and Neck Cancer: Closer Look at Patients Quality of Life. J Cancer Ther. 2016; 7:121–128 TaherAN Head and Neck Cancer: Closer Look at Patients Quality of Life J Cancer Ther 2016 7 121 128 10.4236/jct.2016.72014 Search in Google Scholar

[5] Elting LS, Chang YC. Costs of Oral Complications of Cancer Therapies: Estimates and a Blueprint for Future Study. JNCI Monographs, 2019; 2019(53): lgz010 EltingLS ChangYC Costs of Oral Complications of Cancer Therapies: Estimates and a Blueprint for Future Study JNCI Monographs 2019 2019 53 lgz010 10.1093/jncimonographs/lgz01031425598 Search in Google Scholar

[6] PDQ® Supportive and Palliative Care Editorial Board. PDQ Oral Complications of Chemotherapy and Head/Neck Radiation. Bethesda, MD: National Cancer Institute. Updated <12/16/2016>. PDQ® Supportive and Palliative Care Editorial Board PDQ Oral Complications of Chemotherapy and Head/Neck Radiation Bethesda, MD National Cancer Institute Updated <12/16/2016>. Search in Google Scholar

[7] Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017; 25:1713–1739 VigariosE EpsteinJB SibaudV Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors Support Care Cancer 2017 25 1713 1739 10.1007/s00520-017-3629-428224235 Search in Google Scholar

[8] Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011; 47(6):441–8 WattersAL EpsteinJB AgulnikM Oral complications of targeted cancer therapies: a narrative literature review Oral Oncol 2011 47 6 441 8 10.1016/j.oraloncology.2011.03.02821514211 Search in Google Scholar

[9] Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011; 19:1079–95 doi:10.1007/s00520-011-1197-6 LacoutureME AnadkatMJ BensadounRJ Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities Support Care Cancer 2011 19 1079 95 10.1007/s00520-011-1197-6 312870021630130 Open DOISearch in Google Scholar

[10] Rapoport BL, van Eeden R, Sibaud V, et al. Supportive care for patients undergoing immunotherapy. Support Care Cancer. 2017; 25(10):3017–3030 RapoportBL van EedenR SibaudV Supportive care for patients undergoing immunotherapy Support Care Cancer 2017 25 10 3017 3030 10.1007/s00520-017-3802-928707167 Search in Google Scholar

[11] Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016; 13(8):473–86 doi:10.1038/nrclinonc.2016.58 BoutrosC TarhiniA RoutierE Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination Nat Rev Clin Oncol 2016 13 8 473 86 10.1038/nrclinonc.2016.58 27141885 Open DOISearch in Google Scholar

[12] Nicolatou-Galitis O, Kouri M, Papadopoulou E, et al. Osteonecrosis of the jaw related to nonantiresorptive medications: a systematic review. Support Care Cancer. 2019; 27(2):383–394 Nicolatou-GalitisO KouriM PapadopoulouE Osteonecrosis of the jaw related to nonantiresorptive medications: a systematic review Support Care Cancer 2019 27 2 383 394 10.1007/s00520-018-4501-x30353228 Search in Google Scholar

[13] Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther. 2017; 6:51–71 doi:10.2147/ITT.S141577 DaviesM DuffieldEA Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events Immunotargets Ther 2017 6 51 71 10.2147/ITT.S141577 558492028894725 Open DOISearch in Google Scholar

[14] Lalla, RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014; 120:1453–61 doi:10.1002/cncr.28592 LallaRV BowenJ BaraschA MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy Cancer 2014 120 1453 61 10.1002/cncr.28592 416402224615748 Open DOISearch in Google Scholar

[15] Zeller JL. High suicide risk found for patients with head and neck cancer. JAMA. 2006; 296:1716–1717 ZellerJL High suicide risk found for patients with head and neck cancer JAMA 2006 296 1716 1717 10.1001/jama.296.14.171617032977 Search in Google Scholar

[16] Epstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012; 62(6):400–22 doi:10.3322/caac.21157 EpsteinJB ThariatJ BensadounRJ Oral complications of cancer and cancer therapy: from cancer treatment to survivorship CA Cancer J Clin 2012 62 6 400 22 10.3322/caac.21157 22972543 Open DOISearch in Google Scholar

[17] Saraswat N, Sood A, Kumar D, et al. Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases. Indian Dermatol Online J. 2019; 10(3):251–255 doi:10.4103/idoj.IDOJ_325_18 SaraswatN SoodA KumarD Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases Indian Dermatol Online J 2019 10 3 251 255 10.4103/idoj.IDOJ_325_18 653607631149566 Open DOISearch in Google Scholar

[18] Nicolatou-Galitis O, Kouloulias V, Sotiropoulou-Lountou A, et al. Oral Mucositis, Pain and Xerostomia in 135 Head and Neck Cancer Patients Receiving Radiotherapy with or without Chemotherapy. The Open Cancer Journal. 2011; 4:7–17 Nicolatou-GalitisO KoulouliasV Sotiropoulou-LountouA Oral Mucositis, Pain and Xerostomia in 135 Head and Neck Cancer Patients Receiving Radiotherapy with or without Chemotherapy The Open Cancer Journal 2011 4 7 17 10.2174/1874079001104010007 Search in Google Scholar

[19] Brailo V, Boras VV, Juras DV, et al. Oral Side Effects of Head and Neck Irradiation. 2017; http://dx.doi.org/10.5772/intechopen.68961 BrailoV BorasVV JurasDV Oral Side Effects of Head and Neck Irradiation 2017 http://dx.doi.org/10.5772/intechopen.68961 10.5772/intechopen.68961 Search in Google Scholar

[20] Bowen J, Al-Dasooqi N, Bossi P, et al. The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer. 2019; 27:4023–4033 BowenJ Al-DasooqiN BossiP The pathogenesis of mucositis: updated perspectives and emerging targets Support Care Cancer 2019 27 4023 4033 10.1007/s00520-019-04893-z31286231 Search in Google Scholar

[21] Lalla RV, Brennan MT, Gordon SM, et al. Oral Mucositis Due to High-Dose Chemotherapy and/or Head and Neck Radiation Therapy. JNCI Monographs. 2019; 2019(53):lgz011 LallaRV BrennanMT GordonSM Oral Mucositis Due to High-Dose Chemotherapy and/or Head and Neck Radiation Therapy JNCI Monographs 2019 2019 53 lgz011 Search in Google Scholar

[22] Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent. Clin. North Am. 2014; 58:341–9 LallaRV SaundersDP PetersonDE Chemotherapy or radiation-induced oral mucositis Dent. Clin. North Am 2014 58 341 9 10.1016/j.cden.2013.12.00524655526 Search in Google Scholar

[23] Sroussi HY, Epstein J, Bensadoun RJ, et al. Common oral implications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease and osteoradionecrosis. Cancer Med. 2017; 6(12):2918–31 doi:10.1002/cam4 SroussiHY EpsteinJ BensadounRJ Common oral implications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease and osteoradionecrosis Cancer Med 2017 6 12 2918 31 10.1002/cam4 Open DOISearch in Google Scholar

[24] Bressan V, Stevanin S, Bianchi M, et al. The effects of swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral intake and weight loss in head and neck cancer patients: A systematic review. Cancer Treat Rev. 2016; 45:105–19 doi:10.1016/j.ctrv.2016.03.006] BressanV StevaninS BianchiM The effects of swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral intake and weight loss in head and neck cancer patients: A systematic review Cancer Treat Rev 2016 45 105 19 10.1016/j.ctrv.2016.03.006 Open DOISearch in Google Scholar

[25] Vissink A, Jansma J, Spijkervet FKL, et al. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003; 14(3):199–212 VissinkA JansmaJ SpijkervetFKL Oral sequelae of head and neck radiotherapy Crit Rev Oral Biol Med 2003 14 3 199 212 10.1177/154411130301400305 Search in Google Scholar

[26] Lalla RV, Treister N, Sollecito T, et al. Oral complications at six months after radiation therapy for head and neck cancer. Oral Dis. 2017; 23(8):1134–43 doi:10.1111/odi.12710 LallaRV TreisterN SollecitoT Oral complications at six months after radiation therapy for head and neck cancer Oral Dis 2017 23 8 1134 43 10.1111/odi.12710 Open DOISearch in Google Scholar

[27] Elad S, Zadik Y. Chronic oral mucositis after radiotherapy to the head and neck: a new insight. Support Care Cancer. 2016; 24:4825–30 doi:10.1007/s00520-016-3337-5 EladS ZadikY Chronic oral mucositis after radiotherapy to the head and neck: a new insight Support Care Cancer 2016 24 4825 30 10.1007/s00520-016-3337-5 Open DOISearch in Google Scholar

[28] Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522] J. Clin. Oncol. 2014; 32:2940–50 AngKK ZhangQ RosenthalDI Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522 J. Clin. Oncol. 2014 32 2940 50 10.1200/JCO.2013.53.5633 Search in Google Scholar

[29] Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014; 15: 569–579 PriceTJ PeetersM KimTW Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study Lancet Oncol 2014 15 569 579 10.1016/S1470-2045(14)70118-4 Search in Google Scholar

[30] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11:21–28 BonnerJA HarariPM GiraltJ Radiotherapy plus Cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival Lancet Oncol 2010 11 21 28 10.1016/S1470-2045(09)70311-0 Search in Google Scholar

[31] Magrini SM, Buglione M, Corvò R, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol. 2016; 34:427–435 MagriniSM BuglioneM CorvòR Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial J Clin Oncol 2016 34 427 435 10.1200/JCO.2015.63.167126644536 Search in Google Scholar

[32] Pryor DI, Burmeister E, Burmeister BH, et al. Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2011; 47:984–987 PryorDI BurmeisterE BurmeisterBH Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma Oral Oncol 2011 47 984 987 10.1016/j.oraloncology.2011.07.02321852185 Search in Google Scholar

[33] De Sanctis V, Bossi P, Sanguineti G, et al. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. Crit Rev Oncol Hematol. 2016; 100:147–66] doi:10.1016/j.critrevonc.2016.01.010 De SanctisV BossiP SanguinetiG Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements Crit Rev Oncol Hematol 2016 100 147 66 10.1016/j.critrevonc.2016.01.010 26947812 Open DOISearch in Google Scholar

[34] Zhao B, Zhao H, Zhao J. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events. J Immunother Cancer. 2018; 6(1):101 doi:10.1186/s40425-018-0421-z ZhaoB ZhaoH ZhaoJ Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events J Immunother Cancer 2018 6 1 101 10.1186/s40425-018-0421-z 617117330285872 Open DOISearch in Google Scholar

[35] Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373:1803–1813 MotzerRJ EscudierB McDermottDF Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 2015 373 1803 1813 10.1056/NEJMoa1510665571948726406148 Search in Google Scholar

[36] Lederhandler MH, Ho A, Brinster N, et al. Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab. J Drugs Dermatol. 2018; 17(7):807–809 LederhandlerMH HoA BrinsterN Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab J Drugs Dermatol 2018 17 7 807 809 Search in Google Scholar

[37] Bonomi M, Batt K. Supportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer Patients. Cancers 2015; 7:1743–1757 BonomiM BattK Supportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer Patients Cancers 2015 7 1743 1757 10.3390/cancers7030862458679526404378 Search in Google Scholar

[38] Cramer JD, Johnson JT, Nilsen ML. Pain in Head and Neck Cancer Survivors: Prevalence, Predictors, and Quality-of-Life Impact. Otolaryngol Head Neck Surg. 2018; 159(5):853–8 doi:10.1177/0194599818783964 CramerJD JohnsonJT NilsenML Pain in Head and Neck Cancer Survivors: Prevalence, Predictors, and Quality-of-Life Impact Otolaryngol Head Neck Surg 2018 159 5 853 8 10.1177/0194599818783964 29943677 Open DOISearch in Google Scholar

[39] Jackson LK, Johnson DB, Sosman JA, et al. Oral health in oncology: impact of immunotherapy. Support Care Cancer. 2015; 23(1):1–3 doi:10.1007/s00520-014-2434-6 JacksonLK JohnsonDB SosmanJA Oral health in oncology: impact of immunotherapy Support Care Cancer 2015 23 1 1 3 10.1007/s00520-014-2434-6 25216852 Open DOISearch in Google Scholar

[40] Epstein JB, Wilkie DJ, Fischer DJ, et al. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol. 2009; 1:26 doi:10.1186/1758-3284-1-26 EpsteinJB WilkieDJ FischerDJ Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy Head Neck Oncol 2009 1 26 10.1186/1758-3284-1-26 271796319594943 Open DOISearch in Google Scholar

[41] Lalla RV, Latortue MC, Hong CH, et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer. 2010; 18:985–992 LallaRV LatortueMC HongCH A systematic review of oral fungal infections in patients receiving cancer therapy Support Care Cancer 2010 18 985 992 10.1007/s00520-010-0892-z291479720449755 Search in Google Scholar

[42] Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, et al. Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Support Care Cancer 2006; 14:753–762. Nicolatou-GalitisO AthanassiadouP KoulouliasV Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis Support Care Cancer 2006 14 753 762 10.1007/s00520-005-0006-516402233 Search in Google Scholar

[43] Yarom N, Sroussi H, Elad S. Orofacial Pain in Patients with Cancer and Mucosal Diseases. Contemporary Oral Medicine. 2018; DOI: 10.1007/978-3-319-28100-1_39-1 YaromN SroussiH EladS Orofacial Pain in Patients with Cancer and Mucosal Diseases Contemporary Oral Medicine 2018 10.1007/978-3-319-28100-1_39-1 Open DOISearch in Google Scholar

[44] Viet CT, Corby PM, Akinwande A, et al. Review of Preclinical studies on treatment of Mucositis and Associated Pain. J Dent Res. 2014; 93:868–75. VietCT CorbyPM AkinwandeA Review of Preclinical studies on treatment of Mucositis and Associated Pain J Dent Res 2014 93 868 75 10.1177/0022034514540174421324824943201 Search in Google Scholar

[45] Kouri M, Skapinakis P, Damigos D. Effects of the drugs and interventions, used for the management of cancer treatment-related oral mucositis, on the induced oral pain. The internet journal of Pain, Symptom Control and Palliative Care 2012; 9 (1) doi:10.5580/2c2b KouriM SkapinakisP DamigosD Effects of the drugs and interventions, used for the management of cancer treatment-related oral mucositis, on the induced oral pain The internet journal of Pain, Symptom Control and Palliative Care 2012 9 1 10.5580/2c2b Open DOISearch in Google Scholar

[46] Vadalouca A, Raptis E, Moka E, et al. Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature. Pain Pract. 2012; 12:219–251 VadaloucaA RaptisE MokaE Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature Pain Pract 2012 12 219 251 10.1111/j.1533-2500.2011.00485.x21797961 Search in Google Scholar

[47] Carrozzo M, Eriksen JG, Bensadoun RJ, et al. Oral Mucosal Injury Caused by Targeted Cancer Therapies. J Natl Cancer Inst Monogr. 2019; 2019(53). pii: lgz012 doi:10.1093/jncimonographs/lgz012 CarrozzoM EriksenJG BensadounRJ Oral Mucosal Injury Caused by Targeted Cancer Therapies J Natl Cancer Inst Monogr 2019 2019 53 pii: lgz012 10.1093/jncimonographs/lgz012 31425602 Open DOISearch in Google Scholar

[48] Villa A, Sonis S. Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. Curr Probl Cancer. 2016; 40:244–257 VillaA SonisS Toxicities associated with head and neck cancer treatment and oncology-related clinical trials Curr Probl Cancer 2016 40 244 257 10.1016/j.currproblcancer.2016.06.00127520848 Search in Google Scholar

[49] Villa A, Wolff A, Narayana N, et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction Oral Diseases. 2016; 22, 365–382 VillaA WolffA NarayanaN World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction Oral Diseases 2016 22 365 382 10.1111/odi.1240226602059 Search in Google Scholar

[50] Pinna R, Campus G, Cumbo E, et al. Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage. Therapeutics and Clinical Risk Management 2015; 11:171–188 PinnaR CampusG CumboE Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage Therapeutics and Clinical Risk Management 2015 11 171 188 10.2147/TCRM.S70652432583025691810 Search in Google Scholar

[51] Konings AWT, Coppes RP, Vissink A. On the mechanism of salivary gland radiosensitivity. Int. J. Radiation Oncology Biol Phys 2005; 62(4):1187–1194 KoningsAWT CoppesRP VissinkA On the mechanism of salivary gland radiosensitivity Int. J. Radiation Oncology Biol Phys 2005 62 4 1187 1194 10.1016/j.ijrobp.2004.12.05115990024 Search in Google Scholar

[52] Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017; 23(14 Suppl):259–265 AdelN Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies Am J Manag Care 2017 23 14 Suppl 259 265 Search in Google Scholar

[53] Moreno J, Sahade M, del Giglio A. Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer. 2005; 13:850–853. MorenoJ SahadeM del GiglioA Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study Support Care Cancer 2005 13 850 853 10.1007/s00520-005-0817-415838618 Search in Google Scholar

[54] Jain T, Bhandari A, Ram V, et al. Drug interactions and adverse drug reactions in hospitalized psychiatric patients: a critical element in providing safe medication use. German J Psychiatry. 2011; 14:26–34] JainT BhandariA RamV Drug interactions and adverse drug reactions in hospitalized psychiatric patients: a critical element in providing safe medication use German J Psychiatry 2011 14 26 34 Search in Google Scholar

[55] Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia & Analgesia 2010; 110:604–10] WareMA FitzcharlesMA JosephL ShirY The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial Anesthesia & Analgesia 2010 110 604 10 10.1213/ANE.0b013e3181c76f7020007734 Search in Google Scholar

[56] Yamagishi H, Kawaguchi M. Characterization of centraland peripheral-type benzodiazepine receptors in rat salivary glands. Biochem Pharmacol. 1998; 55: 209–214 YamagishiH KawaguchiM Characterization of centraland peripheral-type benzodiazepine receptors in rat salivary glands Biochem Pharmacol 1998 55 209 214 10.1016/S0006-2952(97)00433-4 Search in Google Scholar

[57] Wang X, Zhang ZY, Wang J, et al. Pharmacokinetics, safety, and tolerability of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(2):160–171 WangX ZhangZY WangJ Pharmacokinetics, safety, and tolerability of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy subjects Clin Pharmacol Drug Dev 2019 8 2 160 171 10.1002/cpdd.58029905976 Search in Google Scholar

[58] Godoy T, Riva A, Ekström J. Atypical antipsychotics-effects of amisulpride on salivary secretion and on clozapine-induced sialorrhea. Oral Dis. 2012; 18(7):680–91 doi:10.1111/j.1601-0825.2012.01926.x GodoyT RivaA EkströmJ Atypical antipsychotics-effects of amisulpride on salivary secretion and on clozapine-induced sialorrhea Oral Dis 2012 18 7 680 91 10.1111/j.1601-0825.2012.01926.x 22458406 Open DOISearch in Google Scholar

[59] Schiff E, Mogilner JG, Sella E, et al. Hypnosis for postradiation xerostomia in head and neck cancer patients: a pilot study. Pain Symptom Manage 2009; 37:1086–1092 SchiffE MogilnerJG SellaE Hypnosis for postradiation xerostomia in head and neck cancer patients: a pilot study Pain Symptom Manage 2009 37 1086 1092 10.1016/j.jpainsymman.2008.07.00519186028 Search in Google Scholar

[60] Hovan AJ, Williams M, Stevenson-Moore P, et al. A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 2010; 18:1081–1087 HovanAJ WilliamsM Stevenson-MooreP A systematic review of dysgeusia induced by cancer therapies Support Care Cancer 2010 18 1081 1087 10.1007/s00520-010-0902-120495984 Search in Google Scholar

[61] Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, et al. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer. 2006; 14:44–51 Nicolatou-GalitisO VelegrakiA Sotiropoulou-LontouA Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy Support Care Cancer 2006 14 44 51 10.1007/s00520-005-0835-215947956 Search in Google Scholar

[62] Wolff A, Joshi RK, Ekström J et al. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D. 2017; 17:1–28 WolffA JoshiRK EkströmJ A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI Drugs R D 2017 17 1 28 10.1007/s40268-016-0153-9531832127853957 Search in Google Scholar

[63] Turner L, Mupparapu M, Akintoye SO. Review of the complications associated with treatment of oropharyngeal cancer: A guide to the dental practitioner. Quintessence Int 2013; 44(3):267–279 TurnerL MupparapuM AkintoyeSO Review of the complications associated with treatment of oropharyngeal cancer: A guide to the dental practitioner Quintessence Int 2013 44 3 267 279 Search in Google Scholar

[64] Elad S, Zadik Y, Hewson I, et al. A Systematic Review of Viral infections Associated with oral involvement in cancer patients; a spotlight on herpesviridea. Support Care Cancer. 2010; 18(8):993–1006 EladS ZadikY HewsonI A Systematic Review of Viral infections Associated with oral involvement in cancer patients; a spotlight on herpesviridea Support Care Cancer 2010 18 8 993 1006 10.1007/s00520-010-0900-320544224 Search in Google Scholar

[65] Elad S, Ranna V, Ariyawardana A, et al. A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions. Support Care Cancer. 2017; 25(2):687–700 doi:10.1007/s00520-016-3477-7 EladS RannaV AriyawardanaA A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions Support Care Cancer 2017 25 2 687 700 10.1007/s00520-016-3477-7 27853930 Open DOISearch in Google Scholar

[66] Panghal M, Kaushal V, Kadayan S, et al. Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols. BMC Oral Health. 2012; 12:22. doi:10.1186/1472-6831-12-22 PanghalM KaushalV KadayanS Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols BMC Oral Health 2012 12 22 10.1186/1472-6831-12-22 349918422817766 Open DOISearch in Google Scholar

[67] Uhlen MM, Tveit AB, Stenhagen KR, et al. Self-induced vomiting and dental erosion-a clinical study. BMC Oral Health. 2014; 14:92 doi:10.1186/1472-6831-14-92 UhlenMM TveitAB StenhagenKR Self-induced vomiting and dental erosion-a clinical study BMC Oral Health 2014 14 92 10.1186/1472-6831-14-92 412559625069878 Open DOISearch in Google Scholar

[68] Galitis E, Droukas V, Tzakis M, et al. Trismus and reduced quality of life in patients with oral squamous cell carcinoma, who received postoperative radiotherapy alone or combined with chemotherapy. Forum of Clinical Oncology. 2017; 8(1):29–36 GalitisE DroukasV TzakisM Trismus and reduced quality of life in patients with oral squamous cell carcinoma, who received postoperative radiotherapy alone or combined with chemotherapy Forum of Clinical Oncology 2017 8 1 29 36 10.1515/fco-2015-0023 Search in Google Scholar

[69] Dijkstra PU, Huisman PM, Roodenburg JLN. Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg 2006; 35:337–342 DijkstraPU HuismanPM RoodenburgJLN Criteria for trismus in head and neck oncology Int J Oral Maxillofac Surg 2006 35 337 342 10.1016/j.ijom.2005.08.00116280237 Search in Google Scholar

[70] Dhanda J1, Pasquier D2, Newman L3, et al. Current Concepts in Osteoradionecrosis after Head and Neck Radiotherapy. Clin Oncol (R Coll Radiol). 2016; 28(7):459–66 doi:10.1016/j.clon.2016.03.002 DhandaJ PasquierD NewmanL Current Concepts in Osteoradionecrosis after Head and Neck Radiotherapy Clin Oncol (R Coll Radiol) 2016 28 7 459 66 10.1016/j.clon.2016.03.002 27038708 Open DOISearch in Google Scholar

[71] Spijkervet FKL, Brennan MT, Peterson DE, et al. Research Frontiers in Oral Toxicities of Cancer Therapies: Osteoradionecrosis of the Jaws. J Natl Cancer Inst Monogr. 2019; 2019(53): pii: lgz006 doi:10.1093/jncimonographs/lgz006 SpijkervetFKL BrennanMT PetersonDE Research Frontiers in Oral Toxicities of Cancer Therapies: Osteoradionecrosis of the Jaws J Natl Cancer Inst Monogr 2019 2019 53 pii: lgz006 10.1093/jncimonographs/lgz006 31425599 Open DOISearch in Google Scholar

[72] Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938–1956 doi:10.1016/j.joms.2014.04.031 RuggieroSL DodsonTB FantasiaJ American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update J Oral Maxillofac Surg 2014 72 10 1938 1956 10.1016/j.joms.2014.04.031 25234529 Open DOISearch in Google Scholar

[73] Nicolatou-Galitis O, Schiødt M, Mendes RA, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 127(2):117–135 doi:10.1016/j.oooo.2018.09.008 Nicolatou-GalitisO SchiødtM MendesRA Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment Oral Surg Oral Med Oral Pathol Oral Radiol 2019 127 2 117 135 10.1016/j.oooo.2018.09.008 30393090 Open DOISearch in Google Scholar

[74] Nicolatou-Galitis O, Razis E, Galiti D, et al. Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120(6):699–706 Nicolatou-GalitisO RazisE GalitiD Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review Oral Surg Oral Med Oral Pathol Oral Radiol 2015 120 6 699 706 10.1016/j.oooo.2015.08.00726455289 Search in Google Scholar

[75] Nicolatou-Galitis O, Papadopoulou E, Vardas E, et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis. 2020; doi:10.1111/odi.13294 Nicolatou-GalitisO PapadopoulouE VardasE Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents Oral Dis 2020 10.1111/odi.13294 32011077 Open DOISearch in Google Scholar

[76] Heifetz-Li JJ, Abdelsamie S, Campbell CB, et al. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 128(5):491–7.e2 doi:10.1016/j.oooo.2019.08.004 Heifetz-LiJJ AbdelsamieS CampbellCB Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw Oral Surg Oral Med Oral Pathol Oral Radiol 2019 128 5 491 7.e2 10.1016/j.oooo.2019.08.004 31488389 Open DOISearch in Google Scholar

[77] Fragulidis G, Pantiora E, Michalaki V, et al. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient. J Oncol Pharm Pract. 2019; 25(2):487–491 doi:10.1177/1078155217738325 FragulidisG PantioraE MichalakiV Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient J Oncol Pharm Pract 2019 25 2 487 491 10.1177/1078155217738325 29067858 Open DOISearch in Google Scholar

[78] Economopoulou P, Nicolatou-Galitis O, Kotsantis I, et al. Nivolumab-related lichen planus of the lip in a patient with head and neck cancer. Oral Oncology. 2020; http://doi.org/10.1016/j.oraloncology.2020.104623 EconomopoulouP Nicolatou-GalitisO KotsantisI Nivolumab-related lichen planus of the lip in a patient with head and neck cancer Oral Oncology 2020 http://doi.org/10.1016/j.oraloncology.2020.104623 10.1016/j.oraloncology.2020.10462332144002 Search in Google Scholar

[79] Cogen AL, Parekh V, Gangadhar T et al. Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma. JAAD Case Rep. 2018; 4(2):132–134 doi:10.1016/j.jdcr.2017.12.002 CogenAL ParekhV GangadharT Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma JAAD Case Rep 2018 4 2 132 134 10.1016/j.jdcr.2017.12.002 578976129387763 Open DOISearch in Google Scholar

[80] Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Current Problems in Cancer. Curr Probl Cancer. 2017; 41(2):125–128 doi:10.1016/j.currproblcancer.2016.12.001 CollinsLK ChapmanMS CarterJB Cutaneous adverse effects of the immune checkpoint inhibitors Current Problems in Cancer. Curr Probl Cancer 2017 41 2 125 128 10.1016/j.currproblcancer.2016.12.001 28190531 Open DOISearch in Google Scholar

[81] Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017; 28(2):368–376 MenziesAM JohnsonDB RamanujamS Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab Ann Oncol 2017 28 2 368 376 10.1093/annonc/mdw44327687304 Search in Google Scholar

[82] Wang H, Mustafa A, Liu S, et al. Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. Front Pharmacol. 2019; 10:1254 doi:10.3389/fphar.2019.01254 WangH MustafaA LiuS Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management Front Pharmacol 2019 10 1254 10.3389/fphar.2019.01254 681943431708780 Open DOISearch in Google Scholar

[83] Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015; 26 Suppl 5:v139–51 doi:10.1093/annonc/mdv202 PetersonDE Boers-DoetsCB BensadounRJ Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up Ann Oncol 2015 26 Suppl 5 v139 51 10.1093/annonc/mdv202 26142468 Open DOISearch in Google Scholar

[84] Basile D, Di Nardo P, Corvaja C, et al. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers (Basel). 2019; 11(6): pii:E857 doi:10.3390/cancers11060857 BasileD Di NardoP CorvajaC Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside Cancers (Basel) 2019 11 6 pii:E857 10.3390/cancers11060857 662728431226812 Open DOISearch in Google Scholar

[85] Larson PJ, Miaskowski C, MacPhail L, et al. The PRO-SELF Mouth Aware program: an effective approach for reducing chemotherapy-induced mucositis. Cancer Nurs. 1998; 21(4):263–268. LarsonPJ MiaskowskiC MacPhailL The PRO-SELF Mouth Aware program: an effective approach for reducing chemotherapy-induced mucositis Cancer Nurs 1998 21 4 263 268 10.1097/00002820-199808000-000079691508 Search in Google Scholar

[86] Hong CHL, Gueiros LA, Fulton JS, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019; 27(10):3949–3967 doi:10.1007/s00520-019-04848-4 HongCHL GueirosLA FultonJS Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines Support Care Cancer 2019 27 10 3949 3967 10.1007/s00520-019-04848-4 31286232 Open DOISearch in Google Scholar

[87] Lopez BC, Esteve CG, Perez MGS. Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent. 2010; 3:31–42 LopezBC EsteveCG PerezMGS Dental treatment considerations in the chemotherapy patient J Clin Exp Dent 2010 3 31 42 Search in Google Scholar

[88] Caribé-Gomes F, Chimenos-Küstner E, López-López J, et al. Dental management of the complications of radio and chemotherapy in oral cancer. Med Oral. 2003; 8(3):178–187 Caribé-GomesF Chimenos-KüstnerE López-LópezJ Dental management of the complications of radio and chemotherapy in oral cancer Med Oral 2003 8 3 178 187 Search in Google Scholar